(CercleFinance.com) – Eli Lilly announced the success of its acquisition of POINT Biopharma Global, a company with a pipeline of therapies in development for the treatment of cancer.
“Next generation radioligand targeted therapies offer great promise for making significant advances against various cancers, and we are excited to invest in this area with the addition of POINT,” explained Jacob Van Naarden, Vice President -executive president at Eli Lilly.
“Over time, I hope we can bring several new ‘radioligandic’ therapies to cancer patients and improve their outcomes,” he added.
At the expiration of the takeover bid, 72,788,215 shares had been tendered to the offer, representing approximately 67.97% of the issued and outstanding shares. These shares have been accepted for payment and will be promptly paid, in accordance with the terms of the offer, at a price of $12.5/share.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
